Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06620003 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jan 23, 2026, no change to tracked fieldsv8-v9
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Apr 2026 to Oct 2026
    • Study completion date: Jul 2026 to Oct 2026
    • Site details revised at 7 of 7 sites
    v7
  3. Primary endpoint revisedv6 Show 4 more changesShow less
    • Interventions: Placebo (Biological), cAd3-Marburg vaccine (Biological) to Placebo (Biological), cAd3-Marburg Vaccine (Biological)
    • Secondary endpoints revised (10)
    • Study description revised
    • Site details revised at 3 of 7 sites
  4. Eligibility criteria expanded, about 3 wordsv5
  5. Site details revised at 2 of 7 sitesv4
Show 2 earlier versionsHide 2 earlier versions
  1. Secondary endpoints: details revised at 5 of 10 entriesv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Primary endpoint revised
    • Study sites: 4 to 7
    • Start date changed from estimate of Jan 2025 to Apr 14, 2025
    • Eligibility criteria expanded, about 48 words
    • Secondary endpoints revised (10)
    • Study description expanded, about 46 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Trial Details
NCT Number NCT06620003
Lead Sponsor Albert B. Sabin Vaccine Institute
Collaborators: Biomedical Advanced Research and Development Authority
Conditions
(from sponsor)		 Marburg Virus Disease
Related terms Marburg Virus Disease
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov